Research graph
References from Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion. Local targets link to admitted publications; unresolved targets remain external evidence.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005 · External reference
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
10.1002/cncr.23401 · 2008 · External reference
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
10.1200/jco.2007.12.2440 · 2007 · External reference
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
10.1200/jco.2002.10.088 · 2002 · External reference
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
10.1158/1078-0432.ccr-08-0260 · 2008 · External reference
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
10.1093/neuonc/nos158 · 2012 · External reference
Integrins: bidirectional, allosteric signaling machines
10.1016/s0092-8674(02)00971-6 · 2002 · External reference
Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells
10.1182/blood-2006-05-023580 · 2006 · External reference
Gene expression profiling of the anti-glioma effect of Cilengitide
10.1186/2193-1801-2-160 · 2013 · External reference
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
10.1186/1756-9966-27-86 · 2008 · External reference
Cilengitide treatment for malignant glioma: current status and future direction
10.2176/nmc.52.539 · 2012 · External reference
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor
10.1158/0008-5472.can-04-3227 · 2005 · External reference
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models
10.1111/j.1440-1789.2012.01344.x · 2013 · External reference
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy
10.1093/jnci/djm229 · 2007 · External reference
The blood-brain barrier/neurovascular unit in health and disease
10.1124/pr.57.2.4 · 2005 · External reference
Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825
10.1093/neuonc/not106 · 2013 · External reference
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
10.1093/neuonc/nop027 · 2010 · External reference
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy
10.1158/1078-0432.ccr-11-2390 · 2012 · External reference
Transforming growth factors β1 (TGF-β1) and TGF-β2 promote glioma cell migration via up-regulation of αVβ3 integrin expression
10.1006/bbrc.2000.2176 · 2000 · External reference
Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin
10.1242/jcs.109.3.643 · 1996 · External reference
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus
10.1038/cgt.2013.38 · 2013 · External reference
Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas
10.1016/j.wneu.2011.09.005 · 2011 · External reference
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme
10.2176/nmc.ra2013-0200 · 2013 · External reference
Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature
10.1097/cad.0b013e3283520e2c · 2012 · External reference
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
10.1016/j.ccr.2012.05.037 · 2012 · External reference
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition
10.1158/1078-0432.ccr-12-1557 · 2013 · External reference
Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells
10.1158/1078-0432.ccr-10-1868 · 2011 · External reference
Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells
10.1007/s11060-006-9121-5 · 2006 · External reference
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model
10.1007/s00401-002-0610-0 · 2003 · External reference
A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion
10.1371/journal.pone.0009808 · 2010 · External reference
Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment
10.1523/jneurosci.3004-12.2013 · 2013 · External reference
